The Gene Box
Diagnostic laboratories

White-label germline NGS and clinical exome interpretation for diagnostic labs, under your brand

Genome, exome and gene panels, plus Clarity for inherited cancer, rare disease and pharmacogenomics, each reported under your lab's name and delivered into your LIMS. No sequencer in-house? Sequencing runs at our partner labs in India, and we run the service end to end, from sample to interpreted report. Your pathologist signs off.

Germline NGS

Germline NGS interpretation: genome, exome, panels

Send us sequencing data or samples. We return interpreted whole-genome, exome and panel reports (including PGx and carrier screening) under your lab's brand, delivered by API and webhook into your LIMS. Every interpretation traces to 150,000 curated references, and clinical findings are routed to a qualified human.

DNA means germline NGS: whole genome, exome, and panels such as drug response (PGx) and carrier screening.

Reports carry the partner laboratory’s brand and are delivered into the LIMS by API and webhooks. Every interpretation traces to 150,000 curated references, and clinical findings are routed to a qualified human. Decision-support, not diagnosis.

Clarity

Clarity: clinical exome module

Inherited cancer (BRCA1/2, Lynch and 18 hereditary cancers in total), rare disease across 3,000+ conditions with trio analysis and ACMG-based variant classification, and carrier screening for 400+ conditions. Released as decision-support for the ordering clinician.

The Gene Box does not diagnose.

Calibrate

Calibrate: PGx reporting

Calibrate provides decision-support reports on drug-gene interactions across 249 drugs, for the prescribing doctor to act on.

LIMS / API

Webhook delivery into the LIMS you already run

The published integration path is REST and JSON, OAuth 2.0, a sandbox, and webhooks when a report is ready. HL7/FHIR R4-compatible exchange is described for EHR and LIS integration. Public endpoint families include /v1/samples, /v1/reports/{id}, microbiome routes, and blood overlay.

The example payload in the proof packet uses those public names. It is an illustrative schema for a scoping conversation. It is not a production contract, and it contains no credentials.

White-label

Multi-omic interpretation under the partner brand

The laboratory keeps the client relationship and the wet-lab. The Gene Box supplies the interpretation layer: blood, DNA and microbiome, each as its own report, with your logo, colours, header, footer, and domain.

White-label content languages already listed on the API page are English, Arabic, and Turkish. The patient-facing and clinician-facing depth can be set by role. The report is still decision-support: it does not replace the ordering clinician.

Blood and multi-omic

Blood (Lens) and multi-omic reports

Already running blood panels, or want gut microbiome on the menu? The same platform interprets them, each as its own report.

Interpreted blood reports on panels the laboratory already runs. Commercial terms are agreed on the pilot call.

Prism (wellness genomics) and Flora (gut microbiome) can be added to a menu when a laboratory asks for them. They are not the hero of a diagnostic-laboratory deployment.

White-label interpretation layer. Blood, DNA and microbiome, each as its own report under the laboratory’s brand, with API delivery into the LIMS. 150,000 curated references behind every report.

Who it’s for

Stakeholders in the laboratory, named the way the work is named

This page is for the people who own the menu, routing of clinical findings, the accession, and the partnership.

Deployment

Integration into the laboratory stack, scoped on a call

Two paths are published today. A RESTful API into the systems you already run, and a white-label platform on your domain. The API page describes API onboarding in days and white-label configuration in weeks. The FAQ describes a laboratory partnership cycle in months. Those sentences are inputs to scoping. They are not a service-level agreement. The call sets the calendar.

Bring the LIMS owner and whoever signs reports. The session maps accessions, the webhook destination, brand files, and the path for routing clinical findings to a qualified human. The scoping outline in the proof packet is the agenda.

Proof packet

Four files a laboratory conversation can use

Sample layout, example payload, scoping agenda, and the compliance line already used on this site. No customer logos and no case studies.

The economics

What the partnership looks like

39
Partners on the engine
11
Countries
150k
Curated references

Commercial terms are agreed on the pilot call.

Scoping

What the pilot call covers

1

Demo

Walk a partner-branded report layout and the decision-support boundary with the people who sign reports.

2

LIMS mapping

Accession identifiers, webhook destination, and the sandbox. No production credentials on the call.

3

Brand and qualified human

Logo, domain, report header and footer, and where clinical findings are routed to a qualified human.

4

Commercial scope

Commercial terms are agreed on the pilot call. This outline is not an SLA.

Qualified human

Decision-support, with a qualified human on the report

Every interpretation is traced to evidence, and clinical findings are routed to a qualified human. The Gene Box does not diagnose. The report is not a medical diagnosis, and the ordering clinician stays responsible for the clinical conversation.

The platform is an interpretation layer for laboratories that already run assays. It is an informatics partnership: your measurement, our reading, your brand on the report.

Proof point

What is already public — and what this page does not add

Founded in Mumbai in 2015. The engine powers reports for 39 partners across 11 countries. Interpretations trace to 150,000 curated references and 1,200+ validated biomarkers. ISO 9001:2015 certified, pursuing ISO 13485, GDPR compliant. Decision-support, not diagnosis — every interpretation traced to evidence, and clinical findings are routed to a qualified human. The homepage logo row for sequencing infrastructure is described there as industry-standard, not an endorsement. This page does not add named laboratory customers or accreditation counts.

Further reading

Go deeper

The challenge

What laboratory operators are working through

Panel volume is rising faster than capacity to route clinical findings to a qualified human

Report layouts change by vendor, so the laboratory’s name goes out in an inconsistent format

Results sit outside the LIMS when there is no API or webhook on the accession

Standing up interpretation in-house means a specialist team, while the wet-lab is already running

Diagnostic chains are asked for genomics, and a single genotyping file does not standardise the report

FAQ

Frequently asked questions

Can The Gene Box interpret germline NGS data (whole genome, exome, panels) under our lab's brand?

Yes. We interpret whole-genome, exome and gene-panel data, including PGx and carrier screening. Reports carry your lab's logo, domain, header and footer, and are delivered into your LIMS by REST API and webhooks.

Do we need our own sequencer?

No. The Gene Box owns no sequencers; sequencing runs at our partner labs in India, and we manage the service end to end, from sample to interpreted report. Labs that already sequence can send data for interpretation only.

What does the Clarity clinical exome module cover?

Inherited cancer (18 hereditary cancers, including BRCA1/2 and Lynch), rare disease (3,000+ conditions, with trio analysis) and carrier screening (400+ conditions). Variants are classified using ACMG guidelines, and clinical findings are routed to a qualified human. It is decision-support, not diagnosis.

How does it connect to our LIMS?

Through a REST/JSON API with OAuth 2.0 and a sandbox, with webhooks when a report is ready. HL7/FHIR R4-compatible exchange is available for LIS/EHR.

Book a pilot call

One path for diagnostic laboratories: LIMS delivery, separate DNA, microbiome and blood reports under your brand, and clinical findings routed to a qualified human. Bring lab operations. Leave with a scoping agenda.